Work

Update of FORTITUDE-ALS: A Phase 2, Double-blind, Randomized, Placebo-Controlled, Study to Evaluate Efficacy, Safety and Tolerability of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (S5.002)

Year: 2019

Type: article

Source: Neurology

DOI: 10.1212/wnl.92.15_supplement.s5.002

Authors: Jeremy Shefner, Jinsy Andrews, Angela Genge, Carlayne Jackson, Noah Lechtzin, Timothy Miller, Bettina Cockroft, Fady Malik, Jenny Wei, Andrew Wolff, Stacy Rudnicki

Institutions: Barrow Neurological Institute, Columbia University Irving Medical Center, Montreal Neurological Institute and Hospital, The University of Texas at San Antonio Health Science Center, Johns Hopkins University, Johns Hopkins Medicine, Washington University in St. Louis, Cytokinetics (United States)

Language: English

Topic: Amyotrophic Lateral Sclerosis Research

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3120873406

FWCI: 0.17

Cites:

Cited by: 1

Related to: 10